Mascarenhas, J. http://orcid.org/0000-0002-8400-0483
Kosiorek, H.
Prchal, J.
Yacoub, A.
Berenzon, D.
Baer, M. R.
Ritchie, E.
Silver, R. T.
Kessler, C.
Winton, E.
Finazzi, M. C.
Rambaldi, A.
Vannucchi, A. M.
Leibowitz, D.
Rondelli, D.
Arcasoy, M. O.
Catchatourian, R.
Vadakara, J.
Rosti, V.
Hexner, E.
Kremyanskaya, M.
Sandy, L.
Tripodi, J.
Najfeld, V.
Farnoud, N.
Salama, M. E.
Weinberg, R. S.
Rampal, R.
Goldberg, J. D.
Mesa, R.
Dueck, A. C.
Hoffman, R.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5P01CA108671-09)
Article History
Received: 13 February 2019
Revised: 11 May 2019
Accepted: 17 May 2019
First Online: 30 July 2019
Compliance with ethical standards
:
: J.M. reports clinical trial research support paid to the institution from Incyte, Roche, Novartis, CTI Biopharma, Janssen, Merck, Promedior, and Celgene; clinical trial steering committee and scientific advisory board member: Roche, CTI Biopharma, Incyte, and Celgene. M.R.B. reports clinical trial research support paid to the institution from Abbvie, AI, Astellas, Forma, Incyte, Kite, and Takeda. M.A. reports research grant support paid to institution from Incyte, CTI Biopharma, Samus Therapeutics, Janssen, and Gilead. R.T.S. reports consultancy and speaker bureau for Pharmaessentia. R.H. reports research support from Roche.